CAR T-cell therapy in autoimmune diseases: where are we and where are we going?

Date publication

mars 2025

Journal

The Lancet. Rheumatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARTIN Thierry

Tous les auteurs :
Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Forcade E, Meyer A, Jorgensen C, Bigenwald C, Cornec D, Sibilia J, Choquet S, Martin T, Belot A, Jouret M, Bitoun S, Amoura Z, Hermine O, Mariette X, Donnadieu E, Avouac J,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40157379

Résumé

Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review we critically discuss the current data available on the use of CAR-based therapy in systemic autoimmune diseases, the current challenges, and the potential next steps toward their implementation into clinical practice. Beyond the targeting of B cells via CD19, we discuss the advantages and potential pitfalls of targeting plasma cells (B-cell Maturation Antigen or CD138) and other non-immune targets, such as fibroblast activated protein, and of aiming to restore immune homeostasis using CAR T regulatory cells. Crucial points need to be addressed for CAR-based therapy to become a viable treatment option for patients with systemic autoimmune diseases.

Référence

Lancet Rheumatol. 2025 03 26;: